Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies
Open Access
- 6 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 44 (4), 467-478
- https://doi.org/10.1007/s40264-020-01041-z
Abstract
Introduction Budesonide-formoterol taken as needed is an emerging treatment for mild asthma. Objective We used data from the SYGMA studies to assess the safety of As-needed budesonide-formoterol compared with As-needed terbutaline and compared with maintenance budesonide. Methods SYGMA 1 and 2 were 52-week, double-blind, parallel-group studies in patients aged ≥ 12 years with physician-assessed mild asthma. Patients were randomized to As-needed budesonide-formoterol 200/6 μg, twice-daily budesonide 200 μg as maintenance plus As-needed terbutaline 0.5 mg, and As-needed terbutaline 0.5 mg (SYGMA 1 only). Adverse events (AEs), serious AEs (SAEs), discontinuations due to AEs (DAEs), and study-defined asthma-related discontinuations from corresponding treatment groups in both studies were pooled. SYGMA 1 data were used for comparisons with As-needed terbutaline alone. Results The pooled analysis included 3366 patients in the As-needed budesonide-formoterol group and 3369 in the budesonide maintenance group, with AEs in 40.8% and 42.5% of patients, respectively. Common AEs included viral upper respiratory tract infection (viral URTI) and URTI. SAE, DAE, and asthma-related discontinuation rates were similar with As-needed budesonide-formoterol and maintenance budesonide. Potential local and systemic corticosteroid class effects were reported in ≤ 1% of patients for each budesonide-containing regimen. In SYGMA 1, AEs were more common in the As-needed terbutaline (n = 1277) than As-needed budesonide-formoterol (n = 1277) groups (42.7 vs. 38.0%), as were DAEs (2.9 vs. 0.8%) and asthma-related discontinuations (1.6 vs. 0.3%). Conclusions Budesonide-formoterol anti-inflammatory reliever therapy is generally well-tolerated in patients with mild asthma and has a safety profile similar to that of daily budesonide. No new safety signals were identified. ClinicalTrial.gov Identifiers NCT02149199 (SYGMA 1) and NCT02224157 (SYGMA 2).Keywords
Funding Information
- AstraZeneca
This publication has 28 references indexed in Scilit:
- As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild AsthmaThe New England Journal of Medicine, 2018
- Inhaled Combined Budesonide–Formoterol as Needed in Mild AsthmaThe New England Journal of Medicine, 2018
- Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent AsthmaJAMA, 2018
- Budesonide/formoterol maintenance and reliever therapy via Turbuhaler versus fixed‐dose budesonide/formoterol plus terbutaline in patients with asthma: Phase III study resultsRespirology, 2012
- Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthmaClinical Therapeutics, 2007
- Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbationsInternational Journal of Clinical Practice, 2007
- Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind studyThe Lancet, 2006
- Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthmaCurrent Medical Research and Opinion, 2004
- Low Dose Inhaled Budesonide and Formoterol in Mild Persistent AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2001